Form 4: Ionis Pharma Executive Sells Shares Under 10b5-1 Plan

Ionis Pharmaceuticals' EVP, CLO & General Counsel, Patrick R. O'Neil, reported the sale of 21,000 common shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals Inc., reported transactions on September 9, 2025.
• O'Neil acquired 20,000 shares of common stock through option exercise at a price of $60.89 per share.
• Concurrently, O'Neil sold 20,000 shares of common stock at a weighted average price of $64.5553 per share, with prices ranging from $64.50 to $64.66.
• Additionally, O'Neil acquired 1,000 shares of common stock through option exercise at a price of $56.78 per share.
• Following this, O'Neil sold 1,000 shares of common stock at the same weighted average price of $64.5553 per share.
• All sales were conducted pursuant to a Rule 10b5-1 Trading Plan adopted by O'Neil on May 2, 2025.
• After these transactions, O'Neil's direct beneficial ownership of common stock stands at 57,130 shares.
• The reporting person holds 57,203 derivative securities (Non-Qualified Stock Options) with an exercise price of $56.78 and 34,461 derivative securities with an exercise price of $60.89.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a Rule 10b5-1 plan, which mitigates the signaling effect. The executive also realized a profit on the exercised options.

Positives

• The insider exercised stock options, indicating value in the underlying shares at the time of exercise.
• The sale price of $64.5553 per share is higher than both exercise prices ($60.89 and $56.78), indicating a profit for the reporting person.

Negatives

• An executive selling shares, even under a pre-arranged plan, can sometimes be perceived as a lack of stronger conviction in the company's immediate future by some investors.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Industry Context

This filing reports routine insider transactions and does not provide information directly related to broader industry trends or competitive landscape. Insider sales are common for executives for diversification or liquidity purposes.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a neutral to slightly negative signal, though the pre-planned nature under Rule 10b5-1 reduces its significance.
• Employees: No direct impact indicated by this filing.

Next Steps

• The reporting person will provide detailed price information for the share sales upon request from Ionis Pharmaceuticals, its security holders, or the SEC staff.

Key Dates

Recommendation

The filing details pre-planned insider sales by an executive under a Rule 10b5-1 plan. While insider selling can sometimes be a negative signal, the pre-arranged nature and the fact that the executive sold shares acquired through option exercise (realizing a profit) suggest it's likely for personal financial planning rather than a reflection of a negative outlook on the company. Without additional information on company performance or strategic shifts, a 'hold' recommendation is appropriate, as this transaction alone does not provide a strong catalyst for a 'buy' or 'sell' decision.

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Options, Rule 10b5-1 Plan, Executive Compensation, Share Sale, Beneficial Ownership